Artiva Biotherapeutics Amends 10-K to Complete Executive, Governance, and Ownership Disclosures

summarizeSummary

Artiva Biotherapeutics filed an amended 10-K to include previously omitted Part III information, detailing executive compensation, board structure, and ownership, while also disclosing multiple late insider trading reports.

check_boxKey Events

• Completion of Annual Report

  The filing amends the original 10-K from March 10, 2026, to include all required Part III information, which was previously omitted, providing a complete annual disclosure.

• Executive Compensation Details

  Provides comprehensive compensation data for named executive officers for 2025 and 2024, including base salaries, performance bonuses, and equity awards, with CEO Fred Aslan's total compensation at $6.67 million in 2025.

• Late Insider Trading Reports

  Discloses that six executive officers, including the CEO, had delinquent Section 16(a) reports in 2025, indicating a lapse in compliance with reporting requirements.

• Significant Institutional Ownership

  Highlights major institutional holders, with RA Capital and affiliates owning 39.9% and GC Corp. and affiliates holding 18.5% of common stock as of March 31, 2026.

auto_awesomeAnalysis

This 10-K/A filing completes the previously incomplete Annual Report on Form 10-K filed on March 10, 2026, by adding critical Part III information regarding directors, executive officers, corporate governance, executive compensation, security ownership, and principal accounting fees. The amendment addresses a significant compliance gap, providing investors with a full picture of the company's leadership, compensation structures, and major shareholders. The disclosure of multiple late Section 16(a) reports by several executive officers indicates a lapse in internal compliance, which is a negative signal. Additionally, the detailed equity compensation plans reveal substantial potential future dilution from authorized shares, which could impact shareholder value.